
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): August 25, 2020

EVOKE PHARMA, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-36075
(Commission
File Number)

20-8447886
(IRS Employer
Identification No.)

420 Stevens Avenue, Suite 370
Solana Beach, California
(Address of Principal Executive Offices)

92075
(Zip Code)

Registrant's telephone number, including area code: (858) 345-1494

(Former Name or Former Address, if Changed Since Last Report.)

Title of each class
Common Stock,
par value \$0.0001 per share

Trading symbol
EVOK

Name of each exchange on which registered
The Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events.

On August 25, 2020, Evoke Pharma, Inc. (the “Company”), and Eversana Life Science Services, LLC (“EVERSANA”), the Company’s commercial partner, announced that EVERSANA has appointed Christopher Quesenberry as Chief Commercial Officer for Gimoti. In June 2020, Gimoti was approved by the Food and Drug Administration for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.

Mr. Quesenberry brings over 30 years of experience in building and executing on commercial strategies for pharmaceutical companies and has held roles across the breadth of sales, marketing and operations. He previously spent 27 years between Novo Nordisk and Merck & Co. culminating in positions of Senior Director in Commercial Strategy, as well as Senior Sales Director in Commercial Operations, respectively. Recently, Mr. Quesenberry served as the Vice President of Global Commercial Effectiveness, providing leadership for Sales, Market Access, Sales Operations in addition to other commercial functions at Nalpropion Pharmaceuticals.

The commercialization collaboration between the Company and EVERSANA calls for a wide collection of business functions to be headed by EVERSANA. Mr. Quesenberry is leading the commercialization efforts across multiple functional teams driving senior decision making for strategy and guiding the building of the sales team amongst other responsibilities.

Safe Harbor Statement

The Company cautions you that statements included in this report that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: the timing of the commercial launch of Gimoti and commercial activities to be conducted by EVERSANA. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this report due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the ability of the Company and the Company’ third party manufacturer, Patheon UK Limited, a subsidiary of Thermo Fischer Scientific Inc. (“Patheon”), to successfully complete the commercial manufacturing of Gimoti; the Company’s and EVERSANA’s ability to successfully launch and drive market demand for Gimoti and the timing thereof; the Company’s ability to obtain additional financing as needed to support its operations, including through its existing line of credit with EVERSANA which is subject to certain customary conditions; the COVID-19 pandemic may disrupt the Company’s, Patheon’s and EVERSANA’s business operations impairing the ability to manufacture or commercialize Gimoti and the Company’s ability to generate any product revenue; the Company’s dependence on third parties for the manufacture of Gimoti; the Company is entirely dependent on the success of Gimoti; inadequate efficacy or unexpected adverse side effects relating to Gimoti that could delay or prevent commercialization, or that could result in recalls or product liability claims; our ability to obtain and maintain intellectual property protection for Gimoti; and other risks detailed

in the Company's prior periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the Company undertakes no obligation to revise or update this report to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EVOKE PHARMA, INC.

Date: August 25, 2020

By: /s/ Matthew J. D'Onofrio
Name: Matthew J. D'Onofrio
Title: Executive Vice President,
Chief Business Officer and Secretary